08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

arGentis, University of Tennessee deal

arGentis received exclusive, worldwide rights to the university's ARG301 to treat rheumatoid arthritis. The oral synthetic peptide targeting Type II collagen is in preclinical development. Financial terms were not disclosed. arGentis' ARG201 type...